



Application Serial No. 08/888,057
Attorney Docket No. 000270-012

19. (Amended) An offspring obtained according to the method of claim 2, wherein said offspring has a genotype identical to a prior-existing differentiated cell, fetus or mammal, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

21. (Amended) A transgenic fetus obtained according to the method of claim 3, wherein said transgenic fetus has a genotype identical to a prior-existing differentiated cell, fetus or mammal except for said genetic alteration, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

22. (Amended) A transgenic offspring obtained according to the method of claim 4, wherein said transgenic offspring has a genotype identical to a prior-existing differentiated cell, fetus or mammal except for said genetic alteration, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

26. (Amended) A fetus obtained according to the method of claim 24, wherein said fetus has a genotype identical to a prior-existing differentiated cell, fetus or mammal, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

27. (Amended) An offspring obtained according to the method of claim 25, wherein said offspring has a genotype identical to a prior-existing differentiated cell, fetus or mammal, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

94 33. (Amended) A transgenic CICM cell line obtained according to claim 32, wherein said cell line has a genotype identical to a prior-existing differentiated cell except for said genetic alteration, wherein said prior-existing cell was not created by nuclear transfer techniques.

95 35. (Amended) Differentiated cells obtained by the method of claim 34, wherein said cells have a genotype identical to a prior-existing differentiated cell, and wherein said prior-existing cell was not created by nuclear transfer techniques, and wherein said prior-existing cell is of a different type.

96 47. (Amended) [The method according to claim 29, which further comprises] A method of making a chimeric CICM comprising combining the cloned NT unit of claim 29 with a fertilized embryo to produce a chimera.

48. (Amended) [The method according to claim 47, which further comprises] A method of making a chimeric embryo comprising developing the chimeric CICM cell line of claim 47 to a chimeric embryo.

49. (Amended) A chimeric embryo obtained according to claim 48, wherein at least part of said embryo has a genotype identical to a prior-existing differentiated cell, fetus or mammal, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

50. (Amended) [The method according to claim 48, which further comprises] A method of making a chimeric fetus, comprising developing the chimeric embryo of claim 48 to a chimeric fetus.

51. (Amended) A chimeric fetus obtained according to claim 50, wherein at least part of said chimeric fetus has a genotype identical to a prior-existing differentiated cell, fetus or mammal, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

52. (Amended) [The method according to claim 50, which further comprises] A method of making a chimeric offspring comprising developing the chimeric fetus of claim 50 to a chimeric offspring.

53. (Amended) A chimeric offspring obtained according to claim 52, wherein at least part of said chimeric offspring has a genotype identical to a prior-existing differentiated cell, fetus or mammal, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

54. (Amended) [The method according to claim 47] A method of producing a genetically altered CICM cell line, wherein a desired DNA is inserted, removed or modified in [said] the differentiated pig cell or cell nucleus of claim 47, thereby resulting in the production of a genetically altered NT unit.

55. (Amended) [The method according to claim 54, which further comprises] A method of making a genetically altered embryo comprising developing the [chimeric] genetically altered CICM cell line of claim 54 to a [chimeric] genetically altered embryo.

26 56. (Amended) A [chimeric] genetically altered embryo obtained according to claim 55, wherein said genetically altered embryo has a genotype identical to a prior-existing differentiated cell, fetus or mammal except for said genetic alteration, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

57. (Amended) [The method according to claim 55, which further comprises] A method of making a genetically altered fetus comprising developing the [chimeric] genetically altered embryo to a [chimeric] genetically altered fetus.

58. (Amended) A [chimeric] genetically altered fetus obtained according to claim 57, wherein said genetically altered fetus has a genotype identical to a prior-existing differentiated cell, fetus or mammal except for said genetic alteration, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

59. (Amended) [The method according to claim 57, which further comprises] A method of making a genetically altered offspring comprising developing the [chimeric] genetically altered fetus of claim 57 to a [chimeric] genetically altered offspring.

96 60. (Amended) A [chimeric] genetically altered offspring obtained according to claim 59, wherein said genetically altered offspring has a genotype identical to a prior-existing differentiated cell, fetus or mammal except for said genetic alteration, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

97 76. (Amended) A transgenic pig, wherein said pig has a genotype identical to a prior-existing differentiated cell, fetus or mammal except for said genetic alteration, wherein said prior-existing cell, fetus or mammal was not created by nuclear transfer techniques.

98 78. The method according to claim [45] 46, wherein the pharmaceutically active protein is isolated from milk of the transgenic offspring.

Kindly add the following new claims:

--79. (New) The method of claim 1, wherein said differentiated pig cell is a proliferating cell.

99 80. (New) The method of claim 79, wherein said differentiated proliferating cell has been expanded in culture.

81. (New) The method of claim 29, wherein said differentiated pig cell is a proliferating cell.